From Allie on X24 Oct 2025 12:22
The Moment We All Brace
Dr. Christina Coughlin confirmed what the close watchers already sensed #AVCT’s Therapeutics Division will present its published data from the first ever dual payload pre|CISION peptide drug conjugate system, fresh from the AACR–NCI–EORTC Molecular Targets Congress in Boston.
The meeting itself is jointly organised by three of the field’s most powerful scientific bodies:
• #AACR the American Association for Cancer Research
• #NCI the National Cancer Institute, the U.S. government’s flagship cancer research arm
• #EORTC the European Organisation for Research and Treatment of Cancer
Curators of the Molecular Targets meeting; where biotech and pharma unveil the preclinical and translational breakthroughs that shape the next generation of cancer drugs.
But unlike #ESMO or #ASCO (equal parts medicine and market theatre) AACR–NCI–EORTC is a laboratory with microphones, where mechanistic data meets interrogation from the same minds who advise the FDA and sit on Big Pharma diligence committees.
It’s an entry into the scientific bloodstream; the Sloan Kettering, MD Anderson, and Dana Farber circuit that decides how oncology moves.
It’s where principal investigators overlap with FDA advisers, trial architects double as pharma scouts, and every data slide becomes a pipeline discussion.
These are the institutions that design early trials. Their clinicians chair ODAC panels, sit on programme boards, and hold advisory roles across AstraZeneca, BMS, Novartis, and Merck’s translational units.
When your molecule is dissected in that room, you’re briefing the people shaping tomorrow’s oncology era, a validation level small cap biotechs rarely touch, and scientific acknowledgement from the gatekeepers of both regulation and capital.
History leaves a trail:
• When ImmunoGen first revealed its ADC linker chemistry here, Roche and Sanofi began the exchanges that would lead to billion dollar licensing, ultimately a $10B AbbVie acquisition.
• Alnylam used this same stage to prove its RNAi engine could adapt across diseases, the turning point that transformed RNA therapeutics and built a $25B franchise.
• And long before Moderna was a household name, its early mRNA delivery data debuted here, sparking the partnerships that later built a $100B biotech empire.
So when Avacta’s dual payload preCISION data appears on this stage, it’s an invitation into the professional conversation that decides what becomes the next oncology backbone.
Most companies reach this level of peer review only once their pivotal trials are nearly complete and replication is already baked in.
#AVCT, by contrast, arrives midPhase 1b with human safety, tolerability, and efficacy already in hand and knows exactly what it’s holding.
The data that has NCI collaborations and pharma’s business development teams waiting for permission to pounce.
It’s rare air for a company of Avacta’s size. At
Sign In
Follow the stocks
